Publikationen in Zusammenarbeit mit Forschern von Hospital Miguel Servet (11)

2024

  1. Chronic lymphocytic leukemia patients with chromosome 6q deletion as the sole cytogenetic abnormality display a high frequency of RPS15 mutations and have a poor prognosis

    American Journal of Hematology

  2. Immunoparesis recovery in newly diagnosed transplant ineligible multiple myeloma patients, an independent prognostic factor that complements minimal residual disease

    Annals of Hematology

2021

  1. Real-World Characteristics and Outcome of Patients Treated With Single-Agent Ibrutinib for Chronic Lymphocytic Leukemia in Spain (IBRORS-LLC Study)

    Clinical Lymphoma, Myeloma and Leukemia, Vol. 21, Núm. 12, pp. e985-e999

  2. Treatment patterns and outcomes among nontransplant newly diagnosed multiple myeloma patients in Spain

    Future Oncology, Vol. 17, Núm. 26, pp. 3465-3476

2020

  1. Chronic lymphocytic leukemia patients with IGH translocations are characterized by a distinct genetic landscape with prognostic implications

    International Journal of Cancer, Vol. 147, Núm. 10, pp. 2780-2792

2017

  1. Update of the Grupo Español de Leucemia Linfocítica Crónica clinical guidelines of the management of chronic lymphocytic leukemia

    Medicina Clinica, Vol. 148, Núm. 8, pp. 381.e1-381.e9

2016

  1. Eltrombopag safety and efficacy for primary chronic immune thrombocytopenia in clinical practice

    European Journal of Haematology, Vol. 97, Núm. 3, pp. 297-302

  2. Frequency and prognostic value of resistance/intolerance to hydroxycarbamide in 890 patients with polycythaemia vera

    British Journal of Haematology, Vol. 172, Núm. 5, pp. 786-793

2015

  1. Successful discontinuation of eltrombopag after complete remission in patients with primary immune thrombocytopenia

    American Journal of Hematology, Vol. 90, Núm. 3, pp. E40-E43

  2. Switching to second-generation tyrosine kinase inhibitor improves the response and outcome of frontline imatinib-treated patients with chronic myeloid leukemia with more than 10% of BCR-ABL/ABL ratio at 3 months

    Cancer Medicine, Vol. 4, Núm. 7, pp. 995-1002

2014

  1. Do chronic myeloid leukemia patients with late “warning” responses benefit from “watch and wait” or switching therapy to a second generation tyrosine kinase inhibitor?

    American Journal of Hematology, Vol. 89, Núm. 11, pp. E206-E211